Evidence map›Paper›PMID 40775059›Full record

ReviewPediatric research2025

The potential for identification of biomarkers specific for childhood-onset lupus nephritis using bioinformatics.

Scott E Wenderfer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Scott E WenderferBC Children's Hospital, Nephrology, Vancouver, BC, Canada. scott.wenderfer@cw.bc.ca.ORCID http://orcid.org/0000-0002-8991-8277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioinformatics has the potential to provide new insights into the pathogenic mechanisms of complex childhood-onset diseases. Otoferlin is one example. There has been an upsurge in utilization of bioinformatics techniques to analyze large data sets in systemic lupus and other diseases. While this can result in large numbers of innovative new biomarkers, diagnostics, and targeted therapies, readers should be mindful of the limitations of bioinformatic analyses. In specific, limitations in the size and diversity of the cohorts or bio-specimens used to generate the original datasets may lead to bias. Moreover, the rigor of the data analysis plan is critical to reproducibility of the findings. Systemic lupus erythematous is an extremely heterogeneous syndrome. There are five classes of lupus nephritis and several other non-classifiable histologic forms of lupus kidney disease. There are at least 23 distinct cell types that comprise the kidney parenchyma, and dozens of other types of infiltrating bone-marrow derived cells. In pediatric research, interpretation of bioinformatics data requires an appreciation for age and developmental effects on anatomy and physiology. With informed methodologies, the repurposing of large data sets from pediatric patients for meta-analyses can advance our understanding of childhood illnesses like lupus nephritis. IMPACT: Integrative bioinformatics is a powerful approach to repurpose large data sets for discovery research. The manuscript by Wu et al. in Pediatric Research identifies otoferlin (OTOF) as a promising new diagnostic biomarker of childhood-onset lupus nephritis. Pediatric researchers should gain more appreciation for the available algorithms for analyzing large data sets from multi-omic projects and funding should be targeted for validating findings in childhood-onset diseases.

Indexed as

BiomarkersComputational BiologyLupus NephritisAge of OnsetChildHumansMembrane ProteinsBiomarkersMembrane Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.